Company Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Arecor Therapeutics plc

EPS Revisions

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:01 2024-04-19 am EDT			5-day change	1st Jan Change
128.5 ^GBX	0.00%		-6.55%	-29.59%

Mar. 12	Arecor to develop "holy grail" diabetes treatment with partner TRx	AN
Mar. 12	Arecor Therapeutics plc and Trx Biosciences Limited Announces Research Collaboration for the Formulation Development of an Oral GLP-1 Receptor Agonist Product	CI

Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.

Number of employees: 51

GBP in Million	2021	Weight	2022	Weight	Delta
Biotechnology 100.0 %	1	100.0 %	2	100.0 %	+107.51%

GBP in Million	2021	Weight	2022	Weight	Delta
United Kingdom 47.3 %	0	6.1 %	1	47.3 %	+1,500.00%
United States 32.6 %	1	81.2 %	1	32.6 %	-16.60%
Switzerland 10.0 %	-	-	0	10.0 %	-
India 5.6 %	-	-	0	5.6 %	-
Rest of Europe 4.5 %	0	6.6 %	0	4.5 %	+42.11%

Managers	Title	Age	Since
Sarah Howell CEO	Chief Executive Officer	49	-
Susan Lowther DFI	Director of Finance/CFO	65	18-12-31
Jan Jezek CTO	Chief Tech/Sci/R&D Officer	-	07-07-31
David Gerring PRN	Corporate Officer/Principal	-	-
Fiona Lawrence LAW	General Counsel	-	-
Manjit Rahelu PRN	Corporate Officer/Principal	-	23-04-04

Members of the board	Title	Age	Since
Alan Smith BRD	Director/Board Member	78	-
Christine Soden BRD	Director/Board Member	66	21-04-30
Andrew Richards CHM	Chairman	64	-
Susan Lowther DFI	Director of Finance/CFO	65	18-12-31
Sarah Howell CEO	Chief Executive Officer	49	-
Mohammad Fazeli BRD	Director/Board Member	59	17-08-31
Jeremy Morgan BRD	Director/Board Member	-	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	30,626,986	14,860,334 ( 48.52 %)	0	48.52 %

Name	Equities	%	Valuation
Lombard Odier Asset Management (Europe) Ltd. 5.300 %	1,623,127	5.300 %	3 M p
Oxford Technology Management Ltd. 5.184 %	1,587,776	5.184 %	3 M p
Chelverton Asset Management Ltd. 4.653 %	1,425,000	4.653 %	3 M p
Unicorn Asset Management Ltd. 3.914 %	1,198,828	3.914 %	2 M p
Sarah Howell 2.833 %	867,738	2.833 %	2 M p
Amati Global Investors Ltd. 2.756 %	844,041	2.756 %	1 M p
Amati Global Investors Ltd. (Venture Capital) 2.721 %	833,246	2.721 %	1 M p
Canaccord Genuity Wealth Ltd. 2.063 %	631,687	2.063 %	1 M p
CRUX Asset Management Ltd. 1.812 %	554,897	1.812 %	981 363 p
Calculus Capital Ltd. 1.402 %	429,474	1.402 %	759 546 p

Arecor Therapeutics Plc

Chesterford Research Park

CB10 1XL, Little Chesterford

+44 1223 426 060

http://www.arecor.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.285 GBP

Average target price

4.71 GBP

Spread / Average Target

+266.54%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARECOR THERAPEUTICS PLC	-29.59%	49.05M
IQVIA HOLDINGS INC.	-2.26%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.06%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.55%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.77%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.27%	11.68B
MEDPACE HOLDINGS, INC.	+20.40%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.78%	11.15B

Other Biotechnology & Medical Research